Dyne therapeutics logo png
WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … WebDyne Therapeutics Information. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in ...
Dyne therapeutics logo png
Did you know?
WebApr 3, 2024 · Catherine Stehman-Breen, M.D., Dyne’s chief medical officer, held senior leadership roles at Amgen and Regeneron Pharmaceuticals, and most recently served … WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ...
WebMay 14, 2024 · Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification. WebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised to date? Dyne Therapeutics has raised $333M. When was the last funding round for Dyne Therapeutics? Dyne Therapeutics closed its last funding round on Jan 21, 2024 from a …
WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1). WebMay 7, 2024 · A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at March 2024, Dyne Therapeutics had cash of US$483m and no debt ...
WebCompany profile page for Dyne Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information
WebDyne Therapeutics has raised a total of $333M in funding over 4 rounds. Their latest funding was raised on Jan 21, 2024 from a Post-IPO Equity round. Dyne Therapeutics … synchro ceaWebDyne Therapeutics. 239 likes · 14 talking about this. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing … thailande framWebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically … Mar 10, 2024: 8-K: Report of unscheduled material events or corporate event. … The Investor Relations website contains information about Dyne Therapeutics, … Amy Reilly. Senior Vice President, Corporate Communications & Investor … thailande footballWebMay 14, 2024 · In January 2024, Dyne reported data showing that two doses (2 x 10 mg/kg) of its lead DM1 candidate resulted in significant toxic human nuclear DMPK knockdown at 14 days. New data being presented ... thaïlande flagWebDec 15, 2024 · The Trade: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes acquired a total of 934,581 shares at an average price of $10.70. To acquire these shares, it cost around $10 million. What ... synchro certificationWebOct 13, 2024 · Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day. October 13, 2024 07:45 ET Source: Dyne Therapeutics, Inc ... synchrochart line ダウンロードWebFeb 9, 2024 · Glassdoor gives you an inside look at what it's like to work at Dyne Therapeutics, including salaries, reviews, office photos, and more. This is the Dyne … thailande foret